Analytical Data
-
基因名
IFN-alpha 10/IFNA10
- Application
-
别名
LeIF C; Interferon alpha-C
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 97% as determined by SDS-PAGE.
-
蛋白编号
P01566
-
表达区间
Cys24~Asp189
-
蛋白长度
Partial
-
分子量
22kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon-alpha 10 (IFN-alpha 10, or IFNA10) is a cytokine belonging to the type I interferon family, which plays a crucial role in the immune response against viral infections and tumors. IFNA10 exhibits antiviral, antiproliferative, and immunomodulatory properties, making it a subject of interest in biomedical research. Its unique expression patterns and functions suggest potential therapeutic applications in various diseases, particularly in cancer and viral infections such as HIV and hepatitis. Research has focused on the recombinant production of IFNA10 to evaluate its efficacy and safety as a therapeutic agent. Advances in biotechnology, such as genetic engineering and recombinant DNA technology, have facilitated the generation of high-purity IFNA10 proteins. Studies have demonstrated that IFNA10 can enhance the immune response by activating immune cells, promoting apoptosis in infected or malignant cells, and upregulating the expression of major histocompatibility complex (MHC) molecules. However, challenges remain in delivering IFNA10 effectively to the target sites and minimizing potential side effects. Ongoing research aims to elucidate the mechanisms of action of IFNA10, explore its potential in combination therapies, and develop novel delivery systems to enhance its therapeutic efficacy.
